CME: Practicing Precision Medicine in Psoriatic Arthritis: Strategies and Digital Health Tools for Managing a Chronic Disease

Practicing Precision Medicine in Psoriatic Arthritis: Strategies and Digital Health Tools for Managing a Chronic Disease

Practicing Precision Medicine in Psoriatic Arthritis: Strategies and Digital Health Tools for Managing a Chronic Disease
RestartResume
With few FDA-approved treatment options for PsA, it's crucial clinicians embrace emerging digital health tools to improve a patient's quality of life.

Available credits: 1.50

Time to complete: 1.5 hours

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Statement of Need

    Psoriatic arthritis (PsA) is a serious and potentially disabling condition that affects approximately 30% of psoriasis patients. In addition to the physical and functional impairments from joint destruction, PsA also negatively impacts relationships, daily activities, work productivity, and overall quality of life. Several agents have been FDA-approved for the treatment of moderate-to-severe PsA since 2008, and there are still more currently under investigation. Digital health tools provide clinicians with multiple touchpoints and reminders; they can help reinforce SMART goals, provide tips, and link to additional resources. Despite the availability of effective PsA agents, clinicians are often not aware of new and pipeline agents for their patients with moderate-to-severe PsA. Often, clinicians are not implementing newer agents or digital health tools into clinical practice that lead to better patient outcomes. 

    In this CME Outfitters Live and On Demand expert faculty will highlight the molecular targets of currently available and emerging biologic treatments for managing PsA, discuss individualized treatment plans, and provide updates on the latest clinical trials focused on the impact of long-term treatment, improving pain, and quality of life.

  • Faculty

    Allan Gibofsky, MD, JD, MACR, FACP, FCLM (Moderator)
    Professor of Medicine, Healthcare Policy and Research
    Weill Medical College of Cornell University
    Attending Rheumatologist
    Hospital for Special Surgery
    New York, NY

    Joel M. Gelfand, MD, MSCE 
    Professor of Dermatology
    Professor of Epidemiology
    Vice Chair of Clinical Research and Medical Director, Dermatology Clinical Studies Unit
    Director, Psoriasis and Phototherapy Treatment Center
    University of Pennsylvania Perelman School of Medicine
    Philadelphia, PA

    Jennifer G. Kwan-Morley, MD 
    Rheumatologist
    Premier Orthopaedics
    Malvern, PA

  • Learning Objectives

    At the end of this CE activity, participants should be able to:

    • Identify the molecular targets of currently available and emerging biologic treatments for the management of PsA.
    • Develop individualized treatment plans for patients with PsA that weigh the risks and benefits of newer agents.
    • Evaluate recent clinical trial data regarding the impact of long-term treatment on improving pain and quality of life.

    The following learning objectives pertain only to those requesting CNE or CPE credit:

    • Identify the molecular targets of currently available and emerging biologic treatments for the management of PsA.
    • Describe individualized treatment plans for patients with PsA that weigh the risks and benefits of newer agents.
    • Evaluate recent clinical trial data regarding the impact of long-term treatment on improving pain and quality of life.
  • Financial Support

    Supported by educational grants from Celgene Corporation; Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.; and Novartis Pharmaceuticals Corporation

  • Target Audience

    Rheumatologists, dermatologists, physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with psoriatic arthritis

  • Credit Information

    CME Credit (Physicians):
    USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    USF Health designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with their participation in this activity.

    CNE Credit (Nurses):
    Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours 

    Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology.  Earn up to 1.5 contact hours of pharmacotherapeutic contact hours. 

    Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

    CPE Credit (Pharmacists):

    CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number: 
    Enduring: 0376-0000-18-018-H01-P 

    Type: Knowledge-based 

    ABIM/MOC Credit: 
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

    Learning Formats 
    Enduring material

    Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

    Post-tests, credit request forms, and activity evaluations must be completed, and participants can print their certificate or statement of credit immediately (75% pass rate required). For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

  • Disclosure Declaration

    It is the policy of USF Health and CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations. 

    Dr. Gibofsky reports that he is on the Speakers Bureau for AbbVie Inc.; Celgene Corporation; Merck & Co., Inc.; and Pfizer, Inc. He is a consultant for AbbVie Inc.; Celgene Corporation; Merck & Co., Inc; Pfizer Inc.; Samumed, LLC; and Sandoz. He is a stock shareholder of AbbVie Inc.; Bristol-Myers Squibb Company; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pfizer Inc.. 

    Dr. Gelfand reports that he receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie Inc.; Celgene Corporation; Janssen Biologics, Inc.; Novartis Corporation, Pfizer Inc.; Ortho Dermatologics, Inc.; and Sanofi. He is a consultant for Bristol-Myers Squibb Company; Boehringer Ingelheim; GlaxoSmithKline; Janssen Biologics, Inc.; Novartis Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; and UCB Data and Safety Monitoring Board (DSMB). 

    Dr. Kwan-Morley has no disclosures to report. 

    Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report. 

    Mae Ochoa, RPh (peer reviewer) has no disclosures to report. 

    Kate Nelson, PHD (planning committee) has no disclosures to report. 

    Sharon Tordoff(planning committee) has no disclosures to report. 

    Jan Perez (planning committee) has no disclosures to report. 

    Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report. 

    Disclosures were obtained from the USF Health staff: No disclosures to report. 

    CME Outfitters, LLC, USF Health, and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use. 

    Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign up for the Rheumatology Academy newsletters.
Comprehensive Rheumatology Education.

Better education for a better you.

* Required
Optional
Rheumatology Updates: Making NORM the Norm
Madelaine A. Feldman, MD, FACR
Register

We’re glad to see you’re enjoying Rheumatology Academy…
but how about a more personalized experience?

Register for free